Composition for hot-melt extrusion and method for producing hot-melt extrusion product using same
US-10016508-B2 · Jul 10, 2018 · US
Composition for hot melt extrusion and method for producing hot melt extrudate by using same
US10646573B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10646573-B2 |
| Application number | US-201414892421-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 3, 2014 |
| Priority date | Jun 3, 2013 |
| Publication date | May 12, 2020 |
| Grant date | May 12, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided is a composition for hot melt extrusion including a drug and hypromellose acetate succinate (HPMCAS) having a hydroxypropoxy molar substitution of 0.40 or more and a mole ratio of an acetyl group to a succinyl group of less than 1.6. Further, provided is a method for producing a hot melt extrudate including the step of hot melt-extruding a composition for hot melt extrusion including a drug and hypromellose acetate succinate having a molar hydroxypropoxy substitution of 0.40 or more and a mole ratio of an acetyl group to a succinyl group of less than 1.6, at a hot melt temperature of not lower than a melting temperature of the hypromellose acetate succinate or of not lower than a temperature at which both the hypromellose acetate succinate and the drug are melted.
First claim
Opening claim text (preview).
The invention claimed is: 1. A composition for hot melt extrusion comprising a drug and hypromellose acetate succinate having a hydroxypropoxy molar substitution of 0.40 or more and a mole ratio of an acetyl group to a succinyl group of less than 1.6. 2. The composition for hot melt extrusion according to claim 1 , wherein the hypromellose acetate succinate has a glass transition temperature Tg of 115° C. or lower. 3. The composition for hot melt extrusion according to claim 1 , wherein the drug is a poorly water-soluble drug. 4. A method for producing a hot melt extrudate comprising the step of hot melt-extruding a composition for hot melt extrusion comprising a drug and hypromellose acetate succinate having a hydroxypropoxy molar substitution of 0.40 or more and a mole ratio of an acetyl group to a succinyl group of less than 1.6, at a hot melt temperature of not lower than a melting temperature of the hypromellose acetate succinate or of not lower than a temperature at which both the hypromellose acetate succinate and the drug are melted. 5. The method for producing a hot melt extrudate according to claim 4 , wherein the hot melt temperature is 50 to 250° C. 6. The composition for hot melt extrusion according to claim 1 , Therein the hydroxypropoxy molar substitution is 0.40 to 0.90. 7. The composition for hot melt extrusion according to claim 1 , wherein the mole ratio of an acetyl group to a succinyl group is 0.8 to 1.3. 8. The composition for hot melt extrusion according to claim 3 , wherein the poorly water-soluble drug is one or more of itraconazole, ketoconazole, fluconazole, miconazole, nifedipine, nitrendipine, amlodipine, nicardipine, nilvadipine, felodipine, efonidipine, ibuprofen, ketoprofen, naproxen, indomethacin, acemetacin, griseofulvin, phenytoin, carbamazepine and dipyridamole. 9. The composition for hot melt extrusion according to claim 1 , further comprising a plasticizer. 10. The composition for hot melt extrusion according to claim 1 , further comprising a surfactant.
Assignees
Inventors
Classifications
Cellulose ether-esters · CPC title
Pre-melted polymers · CPC title
with organic macromolecular compounds · CPC title
Mixed ethers, i.e. ethers with two or more different etherifying groups · CPC title
Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10646573B2 cover?
- Provided is a composition for hot melt extrusion including a drug and hypromellose acetate succinate (HPMCAS) having a hydroxypropoxy molar substitution of 0.40 or more and a mole ratio of an acetyl group to a succinyl group of less than 1.6. Further, provided is a method for producing a hot melt extrudate including the step of hot melt-extruding a composition for hot melt extrusion including a…
- Who is the assignee on this patent?
- Shinetsu Chemical Co
- What technology area does this patent fall under?
- Primary CPC classification A61K47/38. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue May 12 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).